Upadacitinib for Vitiligo at 40 Years
Upadacitinib 15 mg daily is an effective and appropriate treatment for non-segmental vitiligo in a 40-year-old patient, particularly when conventional therapies (topical steroids, topical calcineurin inhibitors, or phototherapy) have failed or are inadequate.
Evidence Base
The most recent and highest-quality evidence comes from two phase 3 randomized controlled trials (Viti-Up-1 and Viti-Up-2) published in 2026 1. These studies demonstrated that upadacitinib 15 mg daily achieved clinically meaningful repigmentation in both facial and total body vitiligo:
- T-VASI 50 (≥50% total body repigmentation) at 48 weeks: 19-21% with upadacitinib vs 6% with placebo (p<0.001)
- F-VASI 75 (≥75% facial repigmentation) at 48 weeks: 23-25% with upadacitinib vs 6-7% with placebo (p<0.001)
These results represent the first FDA-approved systemic therapy specifically for vitiligo, marking a paradigm shift from the 2008 British guidelines 2 which only recommended topical steroids, topical calcineurin inhibitors, and phototherapy.
Treatment Algorithm
Step 1: Assess Disease Characteristics
- Extent: Facial involvement (F-VASI ≥0.5) and total body involvement (T-VASI 5-50)
- Type: Non-segmental vitiligo (upadacitinib is studied for this type)
- Activity: Progressive vs stable disease
- Impact: Quality of life assessment, psychological burden
Step 2: Consider Upadacitinib When:
- Conventional treatments (topical steroids for ≤2 months, topical pimecrolimus/tacrolimus, or NB-UVB phototherapy) have failed 2
- Widespread vitiligo with significant QoL impact 2
- Patient desires systemic therapy for more extensive disease
- Age 12 years or older (approved for adolescents and adults) 1
Step 3: Pre-Treatment Evaluation
Based on JAK inhibitor guidelines 3, 4 and FDA labeling 5:
Required baseline testing:
- Complete blood count with differential
- Liver enzymes (AST, ALT)
- Lipid panel
- Renal function (eGFR)
- Tuberculosis screening (QuantiFERON or PPD)
- Hepatitis B testing (HBsAg, anti-HBc, anti-HBs)
- Pregnancy test (if applicable)
- Cardiovascular risk assessment
History to obtain:
- Prior venous thromboembolism (VTE) events
- Cardiovascular risk factors
- History of malignancy
- Active infections
- Immunosuppressive medication use
Step 4: Dosing
- Standard dose: 15 mg orally once daily 1, 6
- Can be taken with or without food 5
- Do not use with other JAK inhibitors, biologics, or potent immunosuppressants 3
Step 5: Monitoring During Treatment
- Weeks 4-8: CBC, liver enzymes
- Week 12: Lipid panel
- Ongoing: Monitor for infections, particularly herpes zoster
- Clinical assessment: Every 2-3 months with serial photographs 2
Step 6: Expected Timeline
- Continuous repigmentation observed through 52 weeks without plateau 6
- Most patients show progressive improvement over 48 weeks 1
- Combination with 308 nm excimer light may enhance efficacy 7
Safety Considerations
Common Adverse Events
Serious Risks (FDA Class Warnings for JAK Inhibitors) 8, 3, 8
While no major adverse cardiovascular events, VTE, gastrointestinal perforations, tuberculosis, lymphoma, or opportunistic infections (except herpes zoster) were reported in the vitiligo trials 1, the FDA has applied class warnings based on other JAK inhibitor data:
- Increased risk in patients >65 years with cardiovascular risk factors
- VTE risk: Particularly with cardiovascular risk factors, use of oral contraceptives, or Cox-2 inhibitors
- Serious infections: Including tuberculosis reactivation
- Malignancy: Non-melanoma skin cancer, lymphoma
- Major adverse cardiovascular events: In high-risk patients
Contraindications
- Active serious infections
- Severe hepatic impairment (Child-Pugh C) 5
- Pregnancy/breastfeeding (use contraception)
- Combination with biologics or potent immunosuppressants 3
Advantages Over Traditional Vitiligo Treatments
Compared to 2008 guidelines 2 which recommended:
- Topical steroids (limited to 2 months, risk of skin atrophy)
- Topical calcineurin inhibitors (modest efficacy)
- NB-UVB phototherapy (requires 3x/week visits, limited to 200 treatments)
- Oral dexamethasone (NOT recommended due to unacceptable side effects)
Upadacitinib offers:
- Systemic efficacy for widespread disease
- Once-daily oral dosing (improved convenience vs phototherapy)
- Continuous improvement over time
- Both facial and body repigmentation
- No arbitrary treatment limits (unlike phototherapy's 200-treatment cap)
Special Populations
Dose Adjustments
- Moderate renal impairment (eGFR 30-60): No adjustment needed 5
- Severe renal impairment (eGFR 15-30): Use with caution (44% increase in exposure)
- Moderate hepatic impairment (Child-Pugh B): Use with caution (24% increase in AUC)
- Age ≥65 years: Consider cardiovascular risk factors carefully 3
Drug Interactions 5
- Strong CYP3A4 inhibitors (ketoconazole): Increase upadacitinib exposure by 75% - avoid or reduce dose
- Strong CYP3A4 inducers (rifampin): Decrease exposure by 61% - avoid combination
- Methotrexate: No interaction (can be used together if needed)
Clinical Pearls
Upadacitinib represents the first FDA-approved systemic therapy for vitiligo, fundamentally changing the treatment landscape from the 2008 guidelines
Repigmentation is gradual and continuous - set realistic expectations with patients about the 48-week timeline 1
Combination therapy with 308 nm excimer light may enhance outcomes for facial vitiligo 7
The safety profile in vitiligo trials was favorable with no major cardiovascular events or VTE, though class warnings still apply 1
Monitor liver enzymes closely - transient elevations can occur but are usually manageable 9
Consider for multi-system immune comorbidities - case reports show efficacy when vitiligo coexists with alopecia areata, atopic dermatitis, or other immune conditions 10, 9
Baseline skin examination for non-melanoma skin cancer in at-risk patients 3